IFM Investors Pty Ltd Increases Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• IFM Investors Pty Ltd increased its stake in Thermo Fisher Scientific Inc. by 4.3%, acquiring a total of 72,495 shares valued at approximately $29.39 million as of the end of the last reporting period.
• In the latest analyst ratings, Wall Street Zen downgraded Thermo Fisher from a "buy" to a "hold," while Barclays upgraded it from "equal weight" to "overweight" with a price target increase.
• Thermo Fisher has announced a quarterly dividend of $0.43, with a yield of 0.4%, payable to shareholders on record as of September 15th.

IFM Investors Pty Ltd lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 72,495 shares of the medical research company's stock after acquiring an additional 2,976 shares during the quarter. IFM Investors Pty Ltd's holdings in Thermo Fisher Scientific were worth $29,394,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in TMO. GAMMA Investing LLC grew its stake in shares of Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after acquiring an additional 2,415,346 shares during the period. Nuveen LLC bought a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $532,360,000. Sarasin & Partners LLP bought a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $242,991,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $195,049,000. Finally, EdgePoint Investment Group Inc. bought a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $172,139,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on TMO shares. Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, Raymond James Financial reissued an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 0.2%

Shares of TMO traded down $0.92 during midday trading on Tuesday, hitting $474.07. The stock had a trading volume of 1,467,346 shares, compared to its average volume of 2,388,953. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The firm has a market cap of $179.01 billion, a PE ratio of 27.37, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock's 50 day moving average is $472.99 and its 200 day moving average is $448.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 earnings per share. The business's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.